LIGNOSPAN FORTE 36 MCG / 1.8 ML
EPINEPHRINE (EPINEPHRINE BITARTRATE) : 36 MCG / 1.8 ML LIDOCAINE HYDROCHLORIDE : 36 MG / 1.8 ML · DIN 00375799 · SEPTODONT
Health Canada status: MARKETED
What is LIGNOSPAN FORTE?
LIGNOSPAN FORTE 36 MCG / 1.8 ML contains EPINEPHRINE (EPINEPHRINE BITARTRATE) : 36 MCG / 1.8 ML LIDOCAINE HYDROCHLORIDE : 36 MG / 1.8 ML. It is listed in the Health Canada Drug Product Database under DIN 00375799, held by SEPTODONT, supplied as SOLUTION for BLOCK/INFILTRATION administration. Health Canada currently lists it as marketed, status dated 31-Dec-1976. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIGNOSPAN FORTE used for?
Production of local anesthesia for dental procedures by nerve block or infiltration techniques in adults and children.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00375799 |
|---|---|
| Brand name | LIGNOSPAN FORTE |
| Generic / active ingredient | EPINEPHRINE (EPINEPHRINE BITARTRATE) : 36 MCG / 1.8 ML LIDOCAINE HYDROCHLORIDE : 36 MG / 1.8 ML |
| Manufacturer | SEPTODONT |
| Strength | 36 MCG / 1.8 ML |
| Dosage form | SOLUTION |
| Route of administration | BLOCK/INFILTRATION |
| Schedule | Ethical |
| ATC code | N01BB52 LIDOCAINE, COMBINATIONS |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1976 |
| Original market date | 1976-12-31 00:00:00 |
How is it administered?
Inject slowly with frequent aspiration. Dosage based on procedure and patient status. Children: up to 7 mg/kg with epinephrine. Use lowest effective dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text snippet (refer to full monograph).
How is it supplied?
Not explicitly detailed in provided text beyond 'cartridges' implied by dental use and 'parenteral solution' description.
Contraindications
Hypersensitivity to amide-type local anesthetics, sodium metabisulfite, or citric acid.
Warnings and precautions
Risk of dose-related toxicity; ensure resuscitative equipment is available. Avoid intravascular injection. Caution in patients with cardiovascular disease, epilepsy, or hyperthyroidism.
What can be used instead?
Other Canadian products sharing ATC code N01BB52 LIDOCAINE, COMBINATIONS. 16 of 72 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| INSTILLAGEL | 0.05 % | GEL | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02294990 |
| LIDOCAINE 2% AND EPINEPHRINE 1:100,000 | 20 MG | SOLUTION | SEPTODONT | MARKETED | DIN 02473518 |
| LIDOCAINE 2% AND EPINEPHRINE 1:50,000 | 20 MG | SOLUTION | SEPTODONT | MARKETED | DIN 02473526 |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 0.01 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02436221 |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 01901915 |
| LIGNOSPAN STANDARD | 36 MG / 1.8 ML | SOLUTION | SEPTODONT | MARKETED | DIN 00375780 |
| OCTOCAINE HCL 2% EPINEPHRINE 1:100000 | 0.01 MG | SOLUTION | NOVOCOL PHARMACEUTICAL OF CANADA INC | MARKETED | DIN 00151866 |
| PLIAGLIS | 7 % | CREAM | SCIENCES DE LA PEAU CRESCITA INC. / CRESCITA SKIN SCIENCES INC. | MARKETED | DIN 02398028 |
| XYLOCAINE 1% W EPINEPHRINE 1:100000 | 10 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00001791 |
| XYLOCAINE 1% W EPINEPHRINE 1:200000 | 5 MCG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00001805 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.